SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Sees Large Decrease in Short Interest

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the target of a large decline in short interest in the month of February. As of February 15th, there was short interest totalling 8,650,000 shares, a decline of 11.8% from the January 31st total of 9,810,000 shares. Based on an average daily volume of 2,700,000 shares, the days-to-cover ratio is presently 3.2 days.

Hedge Funds Weigh In On SELLAS Life Sciences Group

Several large investors have recently bought and sold shares of SLS. Anson Funds Management LP increased its position in shares of SELLAS Life Sciences Group by 50.2% during the 4th quarter. Anson Funds Management LP now owns 1,192,266 shares of the company’s stock valued at $1,240,000 after purchasing an additional 398,431 shares during the period. Geode Capital Management LLC lifted its stake in SELLAS Life Sciences Group by 21.2% during the fourth quarter. Geode Capital Management LLC now owns 733,546 shares of the company’s stock valued at $763,000 after purchasing an additional 128,355 shares during the last quarter. Brooklyn FI LLC purchased a new position in shares of SELLAS Life Sciences Group in the fourth quarter worth approximately $677,000. Opus Capital Group LLC boosted its stake in SELLAS Life Sciences Group by 5.5% in the 4th quarter. Opus Capital Group LLC now owns 238,500 shares of the company’s stock worth $248,000 after purchasing an additional 12,400 shares during the period. Finally, State Street Corp raised its stake in SELLAS Life Sciences Group by 30.2% during the 3rd quarter. State Street Corp now owns 174,529 shares of the company’s stock valued at $218,000 after purchasing an additional 40,500 shares during the period. Institutional investors and hedge funds own 17.38% of the company’s stock.

SELLAS Life Sciences Group Stock Down 2.0 %

SLS stock traded down $0.03 during mid-day trading on Thursday, reaching $1.21. The company had a trading volume of 71,292 shares, compared to its average volume of 3,269,802. The stock’s 50-day simple moving average is $1.17 and its two-hundred day simple moving average is $1.18. The stock has a market capitalization of $84.81 million, a P/E ratio of -1.75 and a beta of 2.43. SELLAS Life Sciences Group has a one year low of $0.77 and a one year high of $1.84.

SELLAS Life Sciences Group Company Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company’s lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.